February 13, 2024 – UT Southwestern Medical Middle companions with Pfizer Inc. to develop RNA-enhanced supply applied sciences for genetic drugs therapies by means of the Dallas-based medical heart's Program in Genetic Drug Engineering.

This settlement will advance UT Southwestern's analysis and growth of cell-targeted nucleic acid and gene modifying therapies that Pfizer might apply to its portfolio of analysis applications.

The joint effort will deliver collectively UTSW's latest advances in understanding RNA-based biology and improved supply programs for RNA-based therapies with Pfizer's strong and intensive RNA information, speedy manufacturing capabilities and scientific innovation. It has the potential to propel the idea of genetic drugs into new therapeutic areas.

Study extra